WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Students Prepare for National College Entrance Exam in ChinaChinese People Getting Taller: Health AuthoritiesChinese People Getting Taller: Health Authorities(HKSAR 25) Hong Kong's Future Very Promising: Chief Executive Carrie LamDigital Economy Provides Enormous Opportunities for WomenSmart Health Care Hut Offers Residents Great Convenience in East ChinaFarmers Reap Winter Wheat in Gaomiaoli Village, East China's ShandongInt'l Children's Day Celebrated Across ChinaChina's top legislator urges highChina Announces Campaign to Strengthen Psychological Care for Elderly